Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life

Int J STD AIDS. 2018 Feb;29(2):206-207. doi: 10.1177/0956462417747832.

Authors

Emanuela Lattuada¹, Massimiliano Lanzafame^{1

2}, Stefano Nicolè¹, Fabio Rigo¹, Giulia Cucchetto¹, Ercole Concia¹, Sandro Vento^{3

4}

Affiliations

¹ 1 Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.
² 2 Diagnosis and Therapy of HIV Infection Unit, G.B. Rossi University Hospital, Verona, Italy.
³ 3 Department of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
⁴ 4 Nazarbayev University Medical Center, Astana, Kazakhstan.

PMID: 29320967
DOI: 10.1177/0956462417747832

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
HIV Infections / drug therapy*
HIV Infections / virology
HIV Integrase Inhibitors / therapeutic use*
HIV-1 / drug effects*
HIV-1 / isolation & purification*
Heterocyclic Compounds, 3-Ring / therapeutic use*
Humans
Maintenance Chemotherapy / methods*
Middle Aged
Oxazines
Piperazines
Pyridones
RNA, Viral / blood
Sustained Virologic Response
Treatment Outcome
Viral Load

Substances

HIV Integrase Inhibitors
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
RNA, Viral
dolutegravir